RBI-4000 is under clinical development by Replicate Bioscience and currently in Phase I for Rabies. According to GlobalData, Phase I drugs for Rabies have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RBI-4000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RBI-4000 overview
RBI-4000 is under development for the treatment of rabies. The drug candidate is developed based on self-replicating RNA (SynRGY) technology. It is administered through intramuscular route.
It was also under development for the treatment of prostate cancer.
Replicate Bioscience overview
Replicate Bioscience, Inc., a clinical stage biopharmaceutical company that focused on creating novel oncology treatments to prevent drug resistance. The company is headquartered in United States.
For a complete picture of RBI-4000’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
